Synaffix’s antibody-drug conjugate technologies

Synaffix Enters $2 Billion License Agreement with Amgen


Total potential deal value up to $2 billion plus tiered royalties on commercial sales. Synaffix to provide Amgen access to its proprietary antibody-drug conjugate (ADC) technologies.

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), today announced the signing of a licensing agreement with Amgen to develop next generation ADCs.

Synaffix is extremely proud to contribute its ADC-technology and manufacturing expertise to Amgen’s renowned drug development capabilities.

Peter van de Sande, CEO of Synaffix

Amgen will gain access to Synaffix’s antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one ADC program with the option to exercise exclusive research and commercial licenses for an additional four programs at a later date.

Synaffix eligible to receive up to $2 billion in payments

Under the terms of the agreement, Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments, plus tiered royalties on commercial sales which are consistent with the financials of the recently signed licenses of Synaffix ADC technology platform. Amgen will be responsible for the research, development, manufacturing and commercialization of the ADCs and Synaffix will continue to be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

$2bn Potential payments to Synaffix